Encompass Health Co. (NYSE:EHC) Stock Holdings Reduced by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. decreased its position in Encompass Health Co. (NYSE:EHC) by 8.1% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 18,771 shares of the company’s stock after selling 1,648 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Encompass Health were worth $1,734,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. TD Private Client Wealth LLC lifted its stake in shares of Encompass Health by 2,870.0% in the 3rd quarter. TD Private Client Wealth LLC now owns 7,336 shares of the company’s stock valued at $709,000 after purchasing an additional 7,089 shares during the last quarter. Los Angeles Capital Management LLC boosted its stake in shares of Encompass Health by 532.4% during the 3rd quarter. Los Angeles Capital Management LLC now owns 50,290 shares of the company’s stock worth $4,860,000 after acquiring an additional 42,338 shares in the last quarter. Pathstone Holdings LLC increased its holdings in shares of Encompass Health by 54.5% during the 3rd quarter. Pathstone Holdings LLC now owns 21,022 shares of the company’s stock valued at $2,032,000 after acquiring an additional 7,412 shares during the last quarter. Meeder Asset Management Inc. raised its stake in shares of Encompass Health by 43.8% in the 3rd quarter. Meeder Asset Management Inc. now owns 66,405 shares of the company’s stock valued at $6,417,000 after acquiring an additional 20,242 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Encompass Health by 1.2% in the 3rd quarter. Geode Capital Management LLC now owns 1,673,610 shares of the company’s stock worth $161,781,000 after purchasing an additional 20,547 shares during the last quarter. 97.25% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Royal Bank of Canada reissued an “outperform” rating and issued a $110.00 price target on shares of Encompass Health in a research report on Tuesday, February 11th. KeyCorp upped their price target on shares of Encompass Health from $117.00 to $120.00 and gave the company an “overweight” rating in a report on Monday, February 10th. Barclays boosted their price objective on Encompass Health from $116.00 to $118.00 and gave the stock an “overweight” rating in a research report on Friday, February 7th. William Blair reaffirmed an “outperform” rating on shares of Encompass Health in a report on Friday, February 7th. Finally, StockNews.com upgraded Encompass Health from a “hold” rating to a “buy” rating in a report on Saturday, February 15th. Ten research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Encompass Health presently has a consensus rating of “Buy” and an average target price of $107.67.

Insider Buying and Selling at Encompass Health

In other news, CAO Andrew L. Price sold 5,042 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $98.29, for a total transaction of $495,578.18. Following the completion of the sale, the chief accounting officer now owns 69,164 shares of the company’s stock, valued at approximately $6,798,129.56. This trade represents a 6.79 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 2.10% of the company’s stock.

Encompass Health Price Performance

Shares of Encompass Health stock opened at $99.73 on Tuesday. Encompass Health Co. has a twelve month low of $74.27 and a twelve month high of $104.55. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.04 and a current ratio of 1.05. The firm has a market cap of $10.05 billion, a P/E ratio of 22.36, a price-to-earnings-growth ratio of 2.31 and a beta of 0.90. The firm’s 50-day simple moving average is $96.53 and its 200-day simple moving average is $96.50.

Encompass Health (NYSE:EHC) last released its quarterly earnings data on Thursday, February 6th. The company reported $1.17 earnings per share for the quarter, beating analysts’ consensus estimates of $1.05 by $0.12. Encompass Health had a return on equity of 17.56% and a net margin of 8.48%. As a group, research analysts expect that Encompass Health Co. will post 4.8 EPS for the current fiscal year.

Encompass Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 17th. Shareholders of record on Tuesday, April 1st will be paid a dividend of $0.17 per share. The ex-dividend date of this dividend is Tuesday, April 1st. This represents a $0.68 annualized dividend and a yield of 0.68%. Encompass Health’s dividend payout ratio is currently 15.25%.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.